Status:
WITHDRAWN
Spermine Measuring Device Evaluation Protocol
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Prostate Cancer
Eligibility:
MALE
18-100 years
Brief Summary
Prostate gland is a clinically important male sexual organ and its main function is for the production of semen. Globally, it is the second most common cancer in men globally and is also the fifth can...
Detailed Description
Prostate cancer (PC) is highly prevalent worldwide and is currently the 3rd most commonly diagnosed prostate cancer in Hong Kong male population with more than 2000 new cases diagnosed per year. Depen...
Eligibility Criteria
Inclusion
- Adult Chinese male patients with age \> 18 years old
- Clinical indicated for prostate cancer detection and has serum PSA level done within 8 weeks of urine test.
Exclusion
- Patient with recent urinary tract infection within 6 weeks prior to urine collection.
- Patient with recent urethral instrumentation, such as Foley catheter insertion, cystoscopy etc., within 6 weeks prior to urine collection.
- Patient with consumption of 5 alpha reductase inhibitors in past 6 months.
- Patient refused or unable to provide consent for the study
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04339920
Start Date
September 1 2021
End Date
December 1 2021
Last Update
January 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, Hong Kong